Works Cited

1. Federation of State Medical Boards. Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain. Washington, DC: The Federation of State Medical Boards; 2013.

2. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.

3. PR Newswire. U.S. Public and Doctors' Misperceptions Revealed in National Survey Demonstrate Urgent Need for Increased Opioid Dependence Awareness. Available at https://www.prnewswire.com/news-releases/us-public-and-doctors-misperceptions-revealed-in-national-survey-demonstrate-urgent-need-for-increased-opioid-dependence-awareness-210981471.html. Last accessed March 15, 2019.

4. West Virginia Legislature. House Bill 2620. Available at http://www.legis.state.wv.us/Bill_Status/bills_text.cfm?billdoc=HB2620%20SUB.htm&yr=2017&sesstype=RS&i=2620. Last accessed March 15, 2019.

5. Association of American Medical Colleges. Medical Schools Confront Opioid Crisis with Greater Focus on Pain, Addiction Education. Available at https://www.aamc.org/newsroom/newsreleases/464576/medical_schools_confront_opioid_crisis_08042016.html. Last accessed March 15, 2019.

6. Mezei L, Murinson BB. Pain education in North American medical schools. J Pain. 2011;12:1199-208.

7. Oliver J, Coggins C, Compton P, et al. American Society for Pain Management Nursing position statement: pain management in patients with substance use disorders. Pain Management Nursing. 2012;13:169-183.

8. American Psychiatric Association. Changes from DSM-IV-TR to DSM-5. Available at https://dsm.psychiatryonline.org/doi/full/10.1176/appi.books.9780890425596.changes. Last accessed March 15, 2019.

9. West Virginia Board of Pharmacy. Protocol for Pharmacist or interns Furnishing Opioid Antagonist Naloxone Hydrochloride, Developed in Consultation with the DHHR Bureau for Public Health. Available at https://www.wvbop.com/article.asp?ty=CTTS&action2=showArticle&id=14. Last accessed March 15, 2019.

10. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/quality-practice/definition-of-addiction. Last accessed March 15, 2019.

11. Giordano J, Schatman ME, Höver G. Ethical insights to rapprochement in pain care: bringing stakeholders together in the best interest(s) of the patient. Pain Physician. 2009;12:E265-E275.

12. Kenen K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Medicine. 2012;6(2)e41.

13. Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15:ES119-ES133.

14. Miller NS, Greenfeld A. Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone. Am J Ther. 2004;11:26-32.

15. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: U.S. Department of Health and Human Services; 2007.

16. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.

17. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Washington, DC: Department of Veterans Affairs, Department of Defense; 2017.

18. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

19. Sundwall DN, Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, UT: Utah Department of Health; 2009.

20. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116.

21. U.S. Food and Drug Administration. Medication Guides: Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.fda.gov/downloads/Drugs/.../Guidances/UCM244570.pdf. Last accessed March 15, 2019.

22. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442.

23. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.

24. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.

25. Fine PG, Finnegan T, Portenoy RK. Protect your patients, protect your practice: practical risk assessment in the structuring of opioid therapy in chronic pain. J Fam Pract. 2010;59(9 Suppl 2):S1-S16.

26. Katz NP. Opioid Prescribing Toolkit: A Workbook for Clinicians. New York, NY: Oxford University Press; 2010.

27. Strickland JM, Huskey A, Brushwood DB. Pharmacist-physician collaboration in pain management practice. J Opioid Manag. 2007;3:295-301.

28. American Chronic Pain Association. ACPA Resource Guide to Chronic Pain Medication and Treatment: 2018 Edition. Available at https://www.theacpa.org/wp-content/uploads/2018/03/ACPA_Resource_Guide_2018-Final-v2.pdf. Last accessed March 15, 2019.

29. Crespi-Lofton J. VIGIL: answer the question "Is it legitimate?" Pharmacy Today. 2006;12(1):1.

30. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26:552-561.

31. Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: an algorithmic, evidence-based approach. Pain Physician. 2012;15:ES177-ES189.

32. West Virginia Legislature. Senate Bill 627. Available at http://www.legis.state.wv.us/bill_status/bills_text.cfm?billdoc=SB627%20ENR.htm&yr=2016&sesstype=RS&billtype=B&houseorig=S&i=627. Last accessed March 15, 2019.

33. Baxter J. Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain. Available at https://www.drugabuse.gov/nidamed/centers-excellence/resources/minimizing-misuse-prescription-opioids-in-patients-chronic-nonmalignant-pain. Last accessed March 15, 2019.

34. American College of Preventive Medicine. Use, Abuse, Misuse and Disposal of Prescription Pain Medication Patient Guide. Available at https://www.acpm.org/page/UseAbuseRx_PatGuide. Last accessed March 15, 2019.

35. Office of National Drug Control Policy. Proper Disposal of Prescription Drugs. Available at https://www.ncjrs.gov/ondcppubs/publications/pdf/prescrip_disposal.pdf. Last accessed March 15, 2019.

36. Centers for Disease Control and Prevention. Risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR. 2012;61(26):493-497.

37. Hannon K. The Prescription Drug Crisis in New York State: A Comprehensive Approach. Available at https://www.scribd.com/doc/82474334/Prescription-Drug-Abuse-Crisis-in-NYS-Comprehensive-Approach-New. Last accessed March 15, 2019.

38. U.S. Drug Enforcement Administration. Drug Scheduling. Available at https://www.dea.gov/druginfo/drug-scheduling. Last accessed March 15, 2019.

39. West Virginia Code. Chapter 60A: Uniform Controlled Substances Act. Available at http://www.legis.state.wv.us/WVCODE/Code.cfm?chap=60a&art=1. Last accessed March 15, 2019.

40. West Virginia State Senate. Senate Bill 437. Available at http://www.legis.state.wv.us/Bill_Text_HTML/2012_SESSIONS/RS/pdf_bills/sb437%20sub3%20enr%20PRINTED.pdf. Last accessed March 15, 2019.

41. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434-442.

42. West Virginia Board of Pharmacy. Controlled Substances Monitoring Program. Available at http://www.wvbop.com/index.php?option=com_content&view=article&id=99&Itemid=117. Last accessed April 5, 2017.

43. Substance Abuse and Mental Health Services Administration. Results from the 2017 National Survey on Drug Use and Health: Detailed Tables. Available at https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2017/NSDUHDetailedTabs2017.pdf. Last accessed March 15, 2019.

44. Sekhon R, Aminjavahery N, Davis CN Jr, et al. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC). Pain Med. 2013;14(10):1548-1556.

45. Meier B. Increase in Urine Testing Raises Ethical Questions. Available at https://www.nytimes.com/2013/08/02/business/increase-in-urine-testing-raises-ethical-questions.html?_r=0. Last accessed March 15, 2019.

46. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.

47. Holliday S, Hayes C, Dunlop A. Opioid use in chronic non-cancer pain. Part 2: prescribing issues and alternatives. Australian Family Physician. 2013;42:104-111.

48. U.S. Department of Justice Office of Diversion Control. Don't Be Scammed By A Drug Abuser. Available at https://www.deadiversion.usdoj.gov/pubs/brochures/drugabuser.htm. Last accessed March 15, 2019.

49. Eyre E. Drug Firms Poured 780M Painkillers into WV Amid Rise of Overdoses. Available at https://www.wvgazettemail.com/news-health/20161217/drug-firms-poured-780m-painkillers-into-wv-amid-rise-of-overdoses. Last accessed March 15, 2019.

50. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.

51. Thompson GL. The Death Toll of Prescription Drug Abuse: Statistics and Analysis, Past and Present. Available at http://wvsubstancefree.org/docs/WV%20Drug%20Overdose%20Statistics%202001-2013.pdf. Last accessed March 15, 2019.

52. Rudd RA, Seth P, David P, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR. 2016;65(50-51);1445-1452.

53. Jimenez CC. Drinking the Pierian spring: thoughts on things we ought to know. West Virginia Medical Journal. 2010;106(4):4-7.

54. West Virginia Board of Medicine. Legislative Rule 11-10-1: Practitioner Requirements for Accessing the West Virginia Controlled Substances Monitoring Program Database. Available at https://wvbom.wv.gov/download_resource.asp?id=149. Last accessed April 5, 2017.

55. American Medical Association. Code of Ethics: Opinion 1.1.5 Terminating the Patient-Physician Relationship. Available at https://www.ama-assn.org/sites/default/files/media-browser/code-of-medical-ethics-chapter-1.pdf. Last accessed March 15, 2019.

56. Groenewald CB, Rabbitts JA, Gebert JT, Palermo TM. Trends in opioid prescriptions among children and adolescents in the United States: a nationally representative study from 1996 to 2012. Pain. 2016;157(5):1021-1027.

57. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. A Prescriber's Role in Preventing the Diversion of Prescription Drugs. Available at https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Provider-Education-Toolkits/Downloads/prescriber-role-drugdiversion.pdf. Last accessed March 15, 2019.

58. Gutstein HB, Akil H. Opioid analgesics. In: Brunton L, Parker K, Lazo J, Buxton I, Blumenthal D (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011: 547-590.

59. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR. 2015;64(23);631-635.

60. van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635-646.

61. West Virginia Legislature. 2015 Senate Bill 335. Available at http://www.legis.state.wv.us/Bill_Text_HTML/2015_SESSIONS/RS/bills/SB335%20SUB1%20ENR2.pdf. Last accessed March 15, 2019.

62. Lexicomp Online. Available at http://online.lexi.com. Last accessed March 15, 2019.

63. West Virginia Secretary of State. Administrative Law: Title 15 Legislative Rule Series 8 Controlled Substances Monitoring. Available at https://apps.sos.wv.gov/adlaw/csr/ruleview.aspx?document=9546. Last accessed March 15, 2019.

64. West Virginia Department of Health and Human Resources. 2016 West Virginia Overdose Fatality Analysis: Healthcare Systems Utilization, Risk Factors, and Opportunities for Intervention. Available at https://dhhr.wv.gov/bph/Documents/ODCP%20Reports%202017/2016%20West%20Virginia%20Overdose%20Fatality%20Analysis_004302018.pdf. Last accessed March 15, 2019

65. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR. 2016;65(1):1-49.

66. West Virginia Legislature. Senate Bill 431. Available at http://www.legis.state.wv.us/Bill_Status/bills_text.cfm?billdoc=SB431%20enr.htm&yr=2016&sesstype=RS&i=431. Last accessed March 15, 2019.

67. West Virginia Board of Medicine. July 1, 2016 Legislative Changes Regarding the Controlled Substance Monitoring Program Which Directly Impact Licensees. Available at https://wvbom.wv.gov/article.asp?id=28&action2=showArticle&ty=CTTS. Last accessed April 5, 2017.

68. West Virginia Legislature. Senate Bill 273. Available at http://www.wvlegislature.gov/Bill_Status/bills_text.cfm?billdoc=SB273%20INTR.htm&yr=2018&sesstype=RS&i=273. Last accessed March 15, 2019.

69. West Virginia Medical Board. 2018 Legislative Changes Affecting Controlled Substance Prescribing. Available at https://wvbom.wv.gov/article.asp?id=55&action2=showArticle&ty=CTTS. Last accessed March 15, 2019.

Evidence-Based Practice Recommendations Citations

1. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116. Available at https://www.painphysicianjournal.com/2013/april/2013;16;S49-S283.pdf. Last accessed March 15, 2019.



Privacy Policy
Copyright © 2017 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.